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Redistribution of cytoplasmic VEGF to the basolateral aspect
of renal tubular cells in ischemia-reperfusion injury
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kidney may have evolved unique patterns of VEGF regulationRedistribution of cytoplasmic VEGF to the basolateral aspect
to cope with acute hypoxia.of renal tubular cells in ischemia-reperfusion injury.
Background. Vascular endothelial growth factor (VEGF)
mRNA and protein expression are increased by hypoxia in a
variety of cell types and organs. In the kidney, however, chronic
Vascular endothelial growth factor (VEGF) is a potenthypoxia does not up-regulate VEGF mRNA. This suggests that
endothelial cell mitogen that promotes angiogenesis, in-VEGF may be regulated by unique mechanisms in the kidney.
Methods. Unilateral ischemia was induced in rats by vascular creases vascular permeability, and is chemotactic for
cross-clamping (40 min) followed by reperfusion (0, 20, 40, and monocytes [reviewed in 1, 2]. It has potential roles in a
80 min). The distribution of VEGF protein was determined wide variety of situations, including embryogenesis, tu-by immunohistochemical staining and Western blotting. mRNA
mor growth, diabetes, inflammatory responses, and tis-was detected by Northern blotting and semiquantitative re-
sue remodeling [1–8]. Recently, it has also been reportedverse transcription-polymerase chain reaction (RT-PCR). Im-
munohistochemical staining for VEGF was verified using two that VEGF inhibits apoptosis in endothelial cells [9, 10].
VEGF antibodies. To further substantiate the immunohisto- There are three isoforms of VEGF in the rat (VEGF120,chemical findings, laser scanning confocal fluorescence micros-
VEGF164, and VEGF188), arising from alternative splicingcopy was used to demonstrate the distribution of VEGF protein
of mRNA. Monomers are joined by disulfide bonds toin rat renal tubular epithelial cells (NRK52-E) subjected to
hypoxia (40 min) and re-oxygenation (0, 5, 20, 40 and 80 min). form homodimers. The relative abundance of each iso-
Results. Normal kidneys showed diffuse immunohistochem- form varies depending on the organ. In the rat kidney,
ical staining for VEGF in all tubules of the renal cortex and VEGF164 mRNA is the most abundant species, withmedulla. Following ischemia, staining demonstrated a promi-
VEGF188 mRNA being the least abundant [11]. Specificnent shift of cytoplasmic VEGF to the basolateral aspect of
biological characteristics, such as mitogenic activity, bind-tubular cells with both VEGF antibodies. The distribution of
cytoplasmic VEGF returned to normal following 40 and 80 min- ing to heparan sulfate proteoglycans (HSPGs), and se-
utes of reperfusion. Western blots of cytoplasmic samples from cretion, differ markedly between isoforms, suggesting
ischemic kidneys reperfused for 0 and 20 minutes showed de-
unique roles for each [12–15].creased levels of VEGF164 compared with normal (P , 0.01).
Studies performed in vitro have demonstrated similar-VEGF164 and VEGF188 levels in the membrane fraction showed
no change. Northern blots and semiquantitative RT-PCR showed ities between the regulation of VEGF and erythropoietin
no significant up-regulation of VEGF mRNA or change in the (EPO). The expression of VEGF mRNA has been shown
splice pattern. NRK52-E cells subjected to hypoxia and re- to be markedly increased in a variety of cells when theyoxygenation for 0 and 5 minutes showed increased staining for
are made hypoxic or when hypoxia-mimicking tech-VEGF compared with normal, with prominent VEGF staining
niques are used, such as incubation with divalent cationsat the periphery of the cell, similar to the appearance in ische-
mic kidneys. VEGF staining became more diffuse with further (for example, cobalt chloride) [16–22]. Evidence suggests
re-oxygenation. that this occurs via the activation of a heme-containing,
Conclusion. Although synthesis of VEGF mRNA and pro-
oxygen-sensing receptor, which ultimately leads to thetein is not increased during ischemia reperfusion injury, pre-
induction of the transcription factor hypoxia-inducibleexisting VEGF in the tubular cell cytoplasm redistributes to
the basolateral aspect of the cells. These data suggest that the factor-1 (HIF-1) [23]. Studies performed in vivo have
also shown that VEGF mRNA increases in response to
hypoxia [21, 24–26], although this has not been reportedKey words: vascular endothelial growth factor, hypoxia, oxygen, renal
tubules, apoptosis. in the kidney. Two groups have demonstrated a diver-
gence between the regulation of VEGF in vitro and
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endothelial cells, we have examined the expression of 48C (concentration of 2 mg/mL). Negative controls were
performed using an irrelevant, isotype-matched mono-VEGF during ischemia reperfusion injury.
clonal antibody in place of VEGF Ab-5. For VEGF-164
Ab, nonspecific binding was blocked using 10% goat
METHODS
serum prior to incubation with the primary antibody
Ischemia reperfusion injury overnight at 48C (concentration of 0.2 mg/mL). Negative
controls were performed using normal rabbit IgG (Sigma,All experimental protocols were approved by the Eth-
ics Committee of St. Vincent’s Hospital, Melbourne, Vic- St. Louis, MO, USA) in place of VEGF-164 Ab. When
compared with commercially available polyclonal anti-toria, Australia. Outbred male Sprague-Dawley rats
were purchased from Monash University Central Animal bodies for VEGF, such as VEGF-147 (raised against a
fusion protein construct of peptides from human VEGF165Services (Clayton, Victoria, Australia) and were given
free access to food and water. The rats were anesthetized and its 26 amino acid secretory peptide; Santa Cruz Bio-
technology, Inc., Santa Cruz, CA, USA), VEGF-164 Abwith intraperitoneal injections of sodium pentobarbitone
(6 mg/100 g body wt; Nembutal, Abbott Laboratories, produced superior immunohistochemical staining. For
VEGF Ab-5, a peroxidase kit was used for subsequentAustralia), and a midline peritoneal incision was made.
The renal ischemia reperfusion model was produced ac- steps (LSAB 2 Peroxidase kit; Dako, Carpinteria, CA,
USA). For VEGF-164 Ab, peroxidase-conjugated goatcording to standard methods [29–31]. Briefly, the left
renal pedicle was clamped for 40 minutes using nontrau- antirabbit IgG (Zymed, San Francisco, CA, USA) was
used as the secondary antibody, followed by incubationmatic vascular clamps. Variable periods of reperfusion
followed (0, 20, 40, and 80 min), and the left kidneys were with rabbit peroxidase-antiperoxidase (PAP) complexes
(Dako, Glostrup, Denmark). Staining for both antibod-then harvested and processed. The right contralateral
kidneys were removed simultaneously with the left and ies was developed with diaminobenzidine (DAB; Dako,
CA). Counterstaining was performed with hematoxylin.used for comparison. Four rats were used at each time
point, giving a total of 16 left ischemia-reperfused (LIR)
Localization of tubular stainingkidneys and 16 contralateral right normal (RN) kidneys.
Four normal and two sham-operated kidneys were also To determine the location of tubular staining seen
with the VEGF antibodies, sequential sections wereused for comparison.
stained with various tubular markers, as previously de-
Immunohistochemical staining of rat kidney scribed [32, 33]. The fluorescein-labeled lectin Arachis
Hypogea (AH; Sigma) was used to identify distal convo-A variety of fixation methods, VEGF antibodies, and
staining techniques were used before adopting the meth- luted tubules (DCTs) and collecting ducts, while Phaseo-
lus vulgaris erythroagglutinin (PHA-E; Sigma) was usedods described. Frozen sections were superior for the
detection of glomerular VEGF staining, but tubular mor- for proximal convoluted tubules (PCTs). Sheep anti–
Tamm-Horsfall protein (THP) antibody (gift of Dr. H.Y.phology was poor in ischemic kidneys. The immunohisto-
chemistry reported in this study was performed using Lan, Monash Medical Center, Clayton, Victoria, Austra-
lia) was used to identify cortical and medullary thick4-mm-thick paraffin embedded tissue sections fixed in
4% paraformaldehyde. Two different VEGF antibodies ascending limbs of the loop of Henle (TAL). The second-
ary antibodies used were immunoperoxidase-conjugatedwere used to demonstrate VEGF expression in the model,
a monoclonal antibody raised against human VEGF121 anti-FITC Fab fragments (Boehringer Mannheim, Mann-
heim, Germany) for detection of lectin binding and per-(VEGF Ab-5, Clone JH121; Oncogene, Cambridge, MA,
USA) and a polyclonal rabbit antimouse VEGF anti- oxidase-conjugated donkey antisheep IgG (Silenus,
Hawthorn, Australia) for THP binding. Staining was de-body (VEGF-164 Ab; kindly donated by S. Stacker, Lud-
wig Institute for Cancer Research, Melbourne, Victoria, veloped with DAB (Dako, CA) followed by counter-
staining with hematoxylin.Australia). The polyclonal antibody was raised against
a purified preparation of the mouse VEGF164 isoform
Isolation of protein from whole kidneysand has been shown to block VEGF-mediated mitogen-
esis and vascular permeability (unpublished data). The Isolation of cytoplasmic and membrane protein frac-
tions of whole kidneys was performed using a modifica-antibody detects recombinant mouse VEGF164 (R&D Sys-
tems, Minneapolis, MN, USA) on Western blots (data tion of standard techniques [34, 35]. All buffers were
supplemented with protease inhibitors 1 mmol/L phenyl-not shown). Endogenous peroxidase was quenched with
4% hydrogen peroxide in methanol. For VEGF Ab-5, methylsulfonyl fluoride (PMSF), 1 mmol/L leupeptin, and
0.2 mmol/L aprotinin. Each kidney was placed in buffersections were microwaved for 10 minutes in an alkaline
buffer (10 mmol/L Tris-HCl, pH 10.0) after dewaxing. containing 50 mmol/L Tris-HCl, pH 7.4, 150 mmol/L NaCl,
5 mmol/L ethylenediaminetetraacetic acid (EDTA), andNonspecific binding was blocked using 10% swine serum
prior to incubation with primary antibody overnight at homogenized using a pro200 homogenizer (Proscientific
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Inc., Monroe, CT, USA). Homogenates were centrifuged product was cloned into pGEM-T (Promega, Madison,
WI, USA), and the sequence was confirmed by auto-at 700 3 g for five minutes at 48C, and the nuclear pellets
were discarded. Supernatants were then recentrifuged mated sequencing. The VEGF insert was excised from
the vector using the restriction enzymes NcoI and SalIin an ultracentrifuge (100,000 3 g for 60 min at 48C) to
obtain cytoplasmic-enriched samples. The pellets ob- (Promega). A murine GAPDH insert that cross-hybrid-
izes with rat GAPDH was obtained as a 1.2 kb PstItained from this step were solubilized in buffer con-
taining 50 mmol/L Tris-HCl, pH 7.4, 150 mmol/L NaCl, fragment in clone pHcGAP [37].
Total RNA samples were fractionated on a 1% aga-5 mmol/L EDTA, and 0.5% Triton-X-100 and were re-
centrifuged at 12,000 3 g for 15 minutes at 48C to obtain rose-formaldehyde gel and transferred to Genescreen
Plus membranes (NEN Life Sciences, Boston, MA,membrane-enriched samples. Protein concentrations
were determined using the Bradford method (Bio-Rad USA). Membranes were cross-linked using a Strata-
linker (Stratagene, La Jolla, CA, USA) and then prehy-protein assay kit; Bio-Rad Lab., Hercules, CA, USA).
Samples were stored at 2708C until required. bridized for one hour at 658C using Rapid Hyb buffer
(Amersham International, Little Chalfont, Buckingham-
Western blotting shire, UK). Inserts were labeled using the Megaprime
DNA Labeling System (Amersham) and added to freshProtein samples boiled in reducing sample buffer were
resolved on 15% sodium dodecyl sulfate-polyacrylamide Rapid Hyb buffer at 2 3 106 counts/mL hybridization
fluid. Membranes were hybridized for two hours at 658Cgel electrophoresis (SDS-PAGE) gels (40 mg protein/
lane) and transferred to nitrocellulose membranes by and then washed three times for 20 minutes each (first
wash in 2 3 standard saline citrate (SSC)/0.1% SDS atelectroblotting. An affinity-purified rabbit polyclonal an-
tibody to human VEGF was used (VEGF-147; Santa 658C, second wash in 1 3 SSC/0.1% SDS at 658C, third
wash in 0.1 3 SSC/0.1% SDS at room temperature) priorCruz Biotechnology, Inc.) to detect VEGF. The antibody
was raised against a fusion protein with sequences from to exposure to x-ray film (Kodak, Rochester, NY, USA).
Bands were analyzed with densitometry as already de-all four isoforms of human VEGF and is reported to
cross-react with rat VEGF. Following incubation of the scribed for Western blots.
membranes with alkaline phosphatase-conjugated goat
Semiquantitative RT-PCRantirabbit antibody (Zymed), immunoreactive antibod-
ies were detected using CSPDt (Boehringer Mannheim) This assay was performed using a modification of pub-
lished methods [38, 39]. First-strand cDNA was synthe-according to the manufacturer’s specifications. Mem-
branes were washed and then exposed to film. Bands sized from 1 mg of total RNA using AMV-reverse tran-
scriptase (Promega). The subsequent PCR reaction usedwere analyzed by densitometry (Molecular Dynamics
Computing Densitometer, Model 300A, Sunnyvale, CA, primers drawn from exons 1 and 8 of the VEGF gene
sequence (forward 59-TGGACCCTGGCTTTACTGCUSA) using ImageQuant Software (version 3.0).
TGTAC-39 and reverse 59-GGTGAGAGGTCTAGTT
Isolation of total RNA CCCGA-39). These regions are common to all the rat
VEGF isoforms and result in the amplification of threeTotal RNA was extracted from tissues using Trizol
(Life Technologies, GIBCO BRL, Melbourne, Austra- different PCR products (673, 601, and 469 bp). The PCR
reaction was interrupted at five-cycle intervals, and thelia). Whole-tissue samples were homogenized in Trizol
using a pro200 homogenizer (Proscientific Inc. USA). products were analyzed. Levels of VEGF mRNA expres-
sion were assessed by comparing the density of bandsSample RNA levels were quantitated by reading the
absorbance at 260 nm. Final samples were stored at on 2% agarose gels and the cycle of first appearance
of PCR products. Amplification of a 254 bp product2708C until required for Northern blot analysis and sem-
iquantitative reverse transcription-polymerase chain re- representing GAPDH was used to check the efficiency
of the reverse transcription and of the PCR reaction.action (RT-PCR).
GAPDH PCR profiles were compared and equalized.
Northern blotting Duplicate amplifications were performed for each sam-
ple, and the results were shown to be reproducible.A rat VEGF cDNA insert was PCR amplified from
rat mesangial cell RNA using primer sequences obtained
Cell culturefrom the known rat VEGF sequence (Genebank acces-
sion no. M32167) [36]. In order to obtain a single PCR NRK-52E, a nontransformed tubular epithelial cell
line from normal rat kidney (American Type Cultureproduct, the primers chosen were from exon 1 and exon
4, respectively, with exons 1 through 5 being common Collection, Rockville, MD, USA; ATCC No. CRL-1571)
were maintained in Dulbecco’s modified Eagle’s mediumto all three rat isoforms (forward 59-TGGACCCTGGC
TTTACTGCTGTAC-39 and reverse 59-GCAGGAAG supplemented with 15 mmol/L HEPES buffer (GIBCO,
BRL), 10% fetal calf serum, 100 U/mL penicillin, andCTCATCTCTCCTATGTG-39). The resultant 340 bp
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100 mg/mL streptomycin (Commonwealth Serum Labo- and analyzed. Images were obtained and generated on
a confocal laser scanning microscope (Bio-Rad MRCratory, Melbourne, Australia) at 378C in standard incu-
1024; Bio-Rad Microscopy Division, Hemel Hempsteadbators (20% O2, 5% CO2).
Herts, UK).
Laser scanning confocal fluorescence microscopy
StatisticsHypoxia-reoxygenation experiments on NRK52-E
Results from Western and Northern blotting experi-cells were performed essentially as described by Yu et
ments were analyzed using Instat 2.01 (GraphPad Soft-al [40]. NRK52-E cells were grown on 22 3 22 mm
ware). A one-way analysis of variance (ANOVA) wasglass cover slips in complete media as described until
performed to determine whether there was a significantapproximately 50% confluent. Culture plates containing
difference between experimental and control groups.the cells were transferred to an air-tight chamber and
Specific statistical tests used were multiple comparisonincubated in 0% O2 (95% N2 and 5% CO2) for 40 minutes
tests of Bonferroni and Dunnett. P values of less thanat 378C. The chamber was flushed for 20 minutes prior
0.05 were considered significant.to the experiment and received a constant high flow of
the N2/CO2 mixture throughout the hypoxic period. Cells
were re-oxygenated with gas containing a high percent-
RESULTS
age of oxygen (95% O2 and 5% CO2) for 0, 5, 20, 40,
Immunohistochemical staining of rat kidneyand 80 minutes. Cells on cover slips incubated under
normal conditions were also assessed. At the end of the In normal kidneys, VEGF staining was seen in tubules
and glomeruli. The glomerular staining was best seenhypoxic and re-oxygenation periods, cells on the slides
were washed with phosphate-buffered saline (PBS) and with frozen sections (data not shown), with tubular stain-
ing most prominent in paraformaldehyde fixed sections.fixed in 3.2% paraformaldehyde for 15 minutes. Para-
formaldehyde was then neutralized with 150 mmol/L gly- PCTs, DCTs, macula densa, collecting ducts, and loop
of Henle all showed diffuse cytoplasmic staining withcine in PBS for a further 15 minutes. The cells were perme-
abilized with 0.3% Triton X-100 (Bio-Rad), blocked with VEGF Ab-5 (Fig. 1 A, B). With VEGF-164 Ab, particu-
larly intense staining was seen in the cytoplasm of the5% bovine serum albumin for 30 minutes, and then incu-
bated overnight with VEGF Ab-5 in 0.3% Triton X-100 DCT and macula densa, as demonstrated by sequential
staining with the lectin AH (data not shown). Proximaland 0.025% CHAPS (Sigma). Primary antibody concen-
trations and negative controls were as described for im- tubules and collecting ducts showed less intense, diffuse
cytoplasmic staining (Fig. 2B).munohistochemistry. Following incubation with the pri-
mary antibody, the cells were washed once with PBS Kidneys subjected to ischemia and ischemia reperfu-
sion showed pathological features consistent with earlycontaining 0.3% Triton X-100 and 0.025% CHAPS and
then a further two times with PBS alone. Goat antimouse ischemic damage, with evidence of pigmented debris in
tubular lumens, interstitial edema, and swelling of tubu-Oregon green (Molecular Probes, Eugene, OR, USA)
was used as the secondary immunofluorescent antibody lar cells (Figs. 1 C–H and 2 C, D). Tubular sloughing and
cell necrosis were present but not prominent. Kidneys(1-h incubation at room temperature). Cells were washed
three times with PBS and then incubated with propidium subjected to ischemia and not reperfused showed promi-
nent staining for VEGF at the basolateral aspect of tubu-iodide (Sigma) to counterstain the cell nuclei (250 mg/mL
in 1% Triton X-100 for 15 min at room temperature). lar cells in both the cortex and medulla. The appearance
was consistent with a redistribution of the cytoplasmicCells were washed a further three times with PBS, and
then the cover slips were mounted with a water-soluble VEGF. VEGF Ab-5 showed this most prominently, with
the staining appearing in multiple small vesicle-like struc-mount (Aquamount; BDH, Kilsyth, Victoria, Australia)
c
Fig. 1. Immunohistochemical staining for vascular endothelial growth factor (VEGF) in ischemia-reperfused kidneys using a monoclonal antibody
raised against human VEGF121 (VEGF Ab-5). Abbreviations indicate the following structures for all panels: D, distal convoluted tubule (DCT);
P, proximal convoluted tubule (PCT); C, collecting duct; and S, peritubular space. (A and B) Normal kidney showing diffuse cytoplasmic staining
for VEGF in tubules of the cortex (A) and medulla (B). PCT, DCT, macula densa, collecting ducts, and loop of Henle had similar staining. (C–E )
Ischemic kidneys (no reperfusion) showing prominent globular structures with staining for VEGF (arrowheads) at the basolateral aspect of all
tubules of the cortex (C and D) and outer medulla (E). Perinuclear globular structures positive for VEGF are also demonstrated (arrows; D).
The peritubular spaces show expansion consistent with interstitial edema, as well as red cell accumulation and extravasation. (F and G) Ischemic
kidneys reperfused for 20 minutes. There is less basolateral localization of staining for VEGF, with medullary collecting ducts showing prominent,
but more diffuse cytoplasmic staining (F). Some cortical tubules continue to show variable staining for VEGF in globular structures localized to
the basolateral aspect of cells (arrowheads; G). (H) Cortex of ischemic kidney reperfused for 80 minutes, showing prominent, diffuse staining for
VEGF, with less localization to the basolateral area. Negative controls using an isotype-matched irrelevant monoclonal antibody in place of VEGF
Ab-5 showed no staining (data not shown, but appearances were similar to Fig. 2A). Control kidneys (contralateral nonischemic kidneys) showed
VEGF staining similar to normal kidneys (data also not shown). All magnifications 3100 except for E 3150, D 3180, and G 3200.
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Fig. 2. Immunohistochemical staining for VEGF in ischemia-reperfused kidneys using polyclonal VEGF-164 Ab. Abbreviations indicate the
following structures for all panels: C, collecting duct; H, thin segment of Henle’s loop. (A) Negative control using normal rabbit IgG in place of
VEGF-164 Ab. (B) Medulla of normal kidney showing diffuse cytoplasmic staining for VEGF in collecting ducts and the loop of Henle. (C )
Medulla of ischemic kidney (no reperfusion) showing prominent staining for VEGF at the basolateral aspect of collecting duct cells (arrowheads).
(D) Medulla of ischemic kidney reperfused for 20 minutes, showing prominent staining for VEGF at the basolateral aspect of collecting duct cells
(arrowheads). Magnifications: A and B, 3100; C and D, 3150.
tures at the basolateral aspect of the cells (Fig. 1 C–E). and VEGF Ab-5 appearances may be due to different
antibody specificities for the various VEGF isoforms.The redistribution appeared to involve all tubules, in-
cluding PCTs, DCTs, collecting ducts, and loop of Henle. Ischemic kidneys reperfused for 20 minutes also showed
basolateral localization of VEGF in tubular cells usingProminent staining for VEGF was also evident in perinu-
clear vesicle-like structures (Fig. 1D). Using VEGF-164 both VEGF antibodies, although this was not as promi-
nent as that seen in ischemic kidneys not reperfusedAb, similar redistribution of cytoplasmic VEGF was
seen, particularly involving collecting ducts of the me- (Figs. 1 F, G and 2D). In ischemic kidneys reperfused
for 40 and 80 minutes, the appearance was similar todulla (Fig. 2C). Other tubules, particularly cortical PCTs
and DCTs, showed VEGF staining in a more peripheral that seen in normal kidneys, with prominent but diffuse
cytoplasmic VEGF staining in most of the tubules (Fig.location, often along the cell membrane (data not
shown). This minor difference between VEGF-164 Ab 1H). A few tubules continued to show a small degree of
c
Fig. 3. Western blots of cytoplasmic and membrane-enriched protein samples probed with VEGF-147 Ab. (A, top panel) Cytoplasmic fractions.
(Lower panel) Membrane fractions. Normal kidney (lane 1), left ischemia-reperfused (LIR) kidneys (lanes 2 through 5), and contralateral right
normal (RN) kidneys (lanes 6 through 9) are shown. LIR kidneys were subjected to 40 minutes of ischemia with variable reperfusion times
(indicated in minutes). RN kidneys were harvested at the time of LIR kidney removal. Cytoplasmic blots demonstrated a single species (,28 kD).
Membrane blots demonstrated two species (,28 and 31 kD). The blots shown are representative of four separate groups. (B) Densitometric
analysis of cytoplasmic blots (means 6 SD) showing a decrease in VEGF164 to 25% of normal after 40 minutes of ischemia, which persisted despite
20 minutes of reperfusion (LIR 0 and LIR 20; **P , 0.01). Levels returned toward normal after 40 minutes or more of reperfusion (LIR 40 and
LIR 80). Levels in the RN kidneys were similar to normal. (C ) Densitometric analysis of membrane blots (means 6 SD) showing no significant
alteration in VEGF164 and VEGF188 levels in LIR kidneys compared with normal.
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basolateral VEGF localization. Control kidneys (contra- 1 C–E, 2 C, D, and 5 C, D). Following 20 minutes of re-
oxygenation, the majority of cells demonstrated a diffuselateral nonischemic kidneys) showed VEGF staining
similar to normal kidneys (data not shown). cytoplasmic pattern of staining, although occasional cells
continued to show the prominent peripheral staining for
Western blots of cytoplasmic and membrane protein VEGF (Fig. 5E). The VEGF staining became more dif-
from the ischemia-reperfusion model fuse with further re-oxygenation, being similar in cells
re-oxygenated for 40 and 80 minutes (Fig. 5F).Vascular endothelial growth factor isoforms were
identified by apparent molecular weight and comparison
with the mobility of recombinant mouse VEGF164. DISCUSSION
VEGF164 was the predominant isoform in the kidney, in
This study describes the acute redistribution of cyto-agreement with studies reporting relative mRNA expres-
plasmic VEGF to the basolateral aspect of tubular epi-sion [11]. Western blots of cytoplasmic-enriched protein
thelial cells in response to ischemia reperfusion injurysamples demonstrated a consistent decrease in VEGF164
to the kidney. This observation was verified using twolevels following 40 minutes of ischemia (P , 0.01; Fig. 3
different antibodies for VEGF and was supported byA, B). Levels remained at approximately 25% of normal
studies performed using a rat renal tubular epithelialdespite 20 minutes of reperfusion and returned toward
cell line subjected to hypoxia and re-oxygenation. Thisnormal after 40 minutes or more of reperfusion (Fig. 3B).
finding is in contrast to the lack of regulation of VEGFThe membrane-enriched protein samples demonstrated
mRNA and protein in the whole kidney, and suggestsmonomers consistent with the molecular weights of the
that the kidney may use redistribution of pre-existingVEGF164 and VEGF188 isoforms (apparent molecular
VEGF, rather than increased synthesis, to protect endo-weights of 28 and 31 kD, respectively; Fig. 3A). Although
thelial cells during ischemic injury. In the ischemia reper-these sizes were somewhat higher than expected, recom-
fusion model, the basolateral localization was most evi-binant mouse VEGF164 also migrated at a higher than
dent following ischemia and persisted with 20 minutes ofexpected weight on our blots (,28 kD rather than the
reperfusion, although it was less widespread. Re-appear-expected 22 to 23 kD; data not shown). LIR kidneys
ance of the diffuse cytoplasmic staining pattern with fur-showed no change in membrane VEGF164 and VEGF188
ther reperfusion (40 and 80 min) suggests there was alevels compared with normal and control kidneys (Fig.
gradual return to normal VEGF distribution following3 A, C). VEGF120 could not be detected by Western
the re-establishment of the oxygen supply. Similarly,blotting despite the use of a variety of VEGF antibodies.
analysis of NRK52-E cells by confocal microscopy also
Northern blots and semiquantitative RT-PCR demonstrated redistribution of VEGF to the cell periph-
ery following hypoxia. As observed in the ischemia re-Analysis of VEGF mRNA levels by Northern blotting
perfusion model, this appearance persisted into the pe-and semiquantitative RT-PCR showed no significant dif-
riod of early re-oxygenation (5 min) and became moreference in VEGF mRNA expression between the various
diffuse with further re-oxygenation (20, 40, and 80 min).groups of kidneys (Fig. 4). By semiquantitative RT-PCR,
Immunohistochemical studies of VEGF redistributionthree cDNA products were evident, representing the
in ischemic kidneys were, in part, supported by thethree rat VEGF isoforms. The bands first appeared at
results of Western blotting, which showed reduced35 PCR cycles in all groups of the kidneys. Profiles for
VEGF164 in the cytoplasmic fraction. However, resultsnormal, ischemic, ischemic reperfused, and control kid-
from the membrane-enriched samples did not demon-neys all had a similar appearance (data not shown). This
strate the expected increase in VEGF protein levels. Thesupported the Northern blot findings, demonstrating lit-
fate of the VEGF, which was apparently redistributedtle or no change in VEGF mRNA levels in the ischemia-
to the basolateral aspect of the cells, is unknown. Thereperfusion model. Based on data from cobalt chloride
staining at the end of the hypoxic period appeared tostimulated NRK52-E cells, a greater than threefold in-
localize within globular or vesicle-like structures, andcrease in VEGF mRNA was necessary for a change to be
this was also the appearance in cultured cells subjecteddetected by semiquantitative RT-PCR (data not shown).
to hypoxia. The appearance is consistent with the VEGF
Laser scanning confocal fluorescence microscopy being present within the cytoplasm, near the periphery
of the cell, or somehow associated with the membrane.Using VEGF Ab-5, the rat renal tubular epithelial cell
As such, the apparent loss of VEGF from the cytoplasmicline NRK52-E demonstrated slight cytoplasmic VEGF
fraction and the lack of a change in VEGF levels in thestaining (Fig. 5B). Cells subjected to hypoxia and re-
membrane fraction cannot be fully explained. One expla-oxygenated for zero and five minutes showed increased
nation may lie in the possible failure of Western blots tostaining for VEGF compared with normal, with promi-
detect all VEGF isoforms (particularly VEGF120), whereasnent staining at the periphery of the cells (Fig. 5 C, D).
This appearance was similar to that seen in vivo (Figs. this may not have been the case in the immunohisto-
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Fig. 4. Northern blot of total RNA samples, ischemia
reperfusion model. (A) Northern blot demonstrating
VEGF mRNA (single species of approximately 3.7 kb)
relative to GAPDH mRNA. Normal kidney (lane 1),
contralateral normal kidneys (lanes 2 through 5), and
ischemia-reperfused kidneys (lanes 6 through 9) are
shown. The blot is representative of four separate groups.
(B) Densitometric analysis of Northern blots from the
four groups of rats (means 6 SD). Mean VEGF mRNA
levels in the LIR kidneys showed no significant change
compared with normal and RN kidneys.
chemistry. It is possible that the VEGF-containing globu- If VEGF was secreted from the basolateral surface of
the cell during hypoxia, its function would most likelylar structures are intermediates prior to secretion of
be related to recognized actions on endothelial cells,VEGF from the basolateral surface of the cell, although
namely increased vascular permeability, mitogenesis,there is no evidence for this at the present time. It is
and cell migration. Recent reports have also demon-known that the larger VEGF isoforms become anchored
strated a role for VEGF in preventing endothelial cellto the cell surface by their secretory peptide or move to
apoptosis via stimulation of flk-1/KDR or VEGF-R2sites in the extracellular matrix, perhaps bound to HSPG.
[9, 10]. This would be an obvious role for tubular secre-The larger VEGF isoforms are known to associate
tion of VEGF, since survival of a tubular cell duringstrongly with HSPG and are not readily diffusible [41–
hypoxic injury is likely to be critically dependent on the43]. This would allow close proximity to endothelial cells,
survival of the adjacent endothelium. The acute needthe most likely target for VEGF. From these sites, VEGF
for this function would be decreased with re-establish-could be altered by proteolytic processing, for example,
ment of the oxygen supply, possibly explaining the even-
by plasmin or urokinase [12, 41, 42, 44], ultimately diffus- tual return to the diffuse cytoplasmic staining pattern or
ing away from the original site of secretion and influenc- VEGF on re-oxygenation. As there was no evidence for
ing functional VEGF receptors elsewhere. These various increased VEGF mRNA levels, this suggests that the
fragments have shown an ability to bind to VEGF recep- VEGF was further redistributed back to its original loca-
tors with varied endothelial cell mitogenic potencies tion, rather than being made by de novo synthesis or that
[12, 44]. The net effect would be further endothelial cell translation of VEGF protein was somehow increased
stimulation or a competitive inhibition of unmodified without a change in the total amount of VEGF mRNA.
VEGF, depending on the fragments present. Evidence of One of the most striking findings in this study, in con-
smaller species on Western blotting experiments would trast to work in other organs, is the relative lack of regula-
have supported post-translational processing of VEGF tion of VEGF mRNA. Models of hypoxia in the heart
and lungs produce up-regulation of VEGF mRNA ofalong these lines, however, these were not detected.
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Fig. 5. Laser scanning confocal fluorescence
microscopy on NRK52-E subjected to re-oxy-
genation after hypoxia. In all panels, nucleii
were counterstained with propidium iodine.
Staining for VEGF (cytoplasmic) used VEGF
Ab-5. (A) Negative control for VEGF Ab-5
using an irrelevant isotype matched mono-
clonal antibody. (B) Normal NRK52-E show-
ing slight cytoplasmic staining for VEGF. (C
and D) NRK52-E following 40 minutes of hyp-
oxia (C ), and with five minutes of re-oxygen-
ation (D), showing an increase in staining for
VEGF and prominent localization of VEGF
at the periphery of the cells. (E ) NRK52-E
following 40 minutes of hypoxia and 20 min-
utes of re-oxygenation showing diffuse cyto-
plasmic staining for VEGF in most of the cells
(cells at the top of E). Occasional cells showed
persistent peripheral VEGF staining (cells at
the bottom of E). (F) NRK52-E following 40
minutes of hypoxia and 40 minutes of re-oxy-
genation showing diffuse staining for VEGF
in the cytoplasm of cells. Cells re-oxygenated
for 80 minutes had a similar appearance to
cells re-oxygenated for 40 minutes (data not
shown). Magnifications: A, B, and E, 3600;
C and D, 3900; F, 3800.
threefold to fivefold compared with normal [24–26,45]. In regulating the response of the kidney to ischemia and
ischemia reperfusion has not previously been reported.this study, no significant up-regulation of VEGF mRNA
was observed, a finding also made in models of chronic This study describes a novel redistribution of tubular
cell cytoplasmic VEGF protein to the basolateral aspectrenal hypoxia [27, 28, 46]. Since the medulla is already
at oxygen tension levels low enough to lead to VEGF of the cell. There was no significant up-regulation of
VEGF mRNA or protein over the time periods studied,up-regulation in other organs [47–49], it is possible that
the usual regulatory pathways are switched off. However, in contrast to results in other organs, but in keeping with
other studies of hypoxia in the kidney. This work suggestsit is not clear why the kidney is able to regulate transcrip-
tion of EPO in response to chronic hypoxia but not VEGF. that the kidney may have evolved unique patterns of
VEGF regulation to cope with acute hypoxia.In conclusion, the potential importance of VEGF in
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